Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,483,461 shares of the medical equipment provider's stock after selling 121,463 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.54% of Hologic worth $251,123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Benson Investment Management Company Inc. purchased a new position in shares of Hologic during the 4th quarter worth about $4,832,000. Principal Financial Group Inc. increased its position in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after purchasing an additional 1,606 shares during the last quarter. Clean Yield Group raised its stake in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after purchasing an additional 7,266 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Hologic by 44.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock valued at $4,595,000 after buying an additional 19,688 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Royal Bank of Canada reduced their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday. Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Morgan Stanley reduced their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday. Finally, Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $79.85.

Hologic Stock Down 2.6 %

Shares of Hologic stock opened at $52.73 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1-year low of $52.12 and a 1-year high of $84.67. The business has a 50-day moving average of $60.05 and a 200-day moving average of $68.89. The company has a market capitalization of $11.83 billion, a PE ratio of 16.63, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the business earned $1.03 EPS. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.